Although there was no difference in tumor flux for the initial days following addition of doxycycline (Supplementary Fig. S14A), silencing of TFAP4 in NGP tumors significantly prolonged overall survival by 13 days (Supplementary Fig. S14B; median survival 86 vs. 73 days, + Dox vs. − Dox, respectively P = 0.03). The gene discussed is TFAP4; the disease is neoplasm.